408 related articles for article (PubMed ID: 21693436)
1. Estimating the risk of drug-induced proarrhythmia using human induced pluripotent stem cell-derived cardiomyocytes.
Guo L; Abrams RM; Babiarz JE; Cohen JD; Kameoka S; Sanders MJ; Chiao E; Kolaja KL
Toxicol Sci; 2011 Sep; 123(1):281-9. PubMed ID: 21693436
[TBL] [Abstract][Full Text] [Related]
2. An impedance-based approach using human iPSC-derived cardiomyocytes significantly improves in vitro prediction of in vivo cardiotox liabilities.
Koci B; Luerman G; Duenbostell A; Kettenhofen R; Bohlen H; Coyle L; Knight B; Ku W; Volberg W; Woska JR; Brown MP
Toxicol Appl Pharmacol; 2017 Aug; 329():121-127. PubMed ID: 28546047
[TBL] [Abstract][Full Text] [Related]
3. Characterization of human-induced pluripotent stem cell-derived cardiomyocytes: bioenergetics and utilization in safety screening.
Rana P; Anson B; Engle S; Will Y
Toxicol Sci; 2012 Nov; 130(1):117-31. PubMed ID: 22843568
[TBL] [Abstract][Full Text] [Related]
4. Assessment of Proarrhythmic Potential of Drugs in Optogenetically Paced Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
Patel D; Stohlman J; Dang Q; Strauss DG; Blinova K
Toxicol Sci; 2019 Jul; 170(1):167-179. PubMed ID: 30912807
[TBL] [Abstract][Full Text] [Related]
5. Drug-induced functional cardiotoxicity screening in stem cell-derived human and mouse cardiomyocytes: effects of reference compounds.
Himmel HM
J Pharmacol Toxicol Methods; 2013; 68(1):97-111. PubMed ID: 23702537
[TBL] [Abstract][Full Text] [Related]
6. Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model.
Guo L; Coyle L; Abrams RM; Kemper R; Chiao ET; Kolaja KL
Toxicol Sci; 2013 Dec; 136(2):581-94. PubMed ID: 24052561
[TBL] [Abstract][Full Text] [Related]
7. Concise review: Human pluripotent stem cell-based models for cardiac and hepatic toxicity assessment.
Sartipy P; Björquist P
Stem Cells; 2011 May; 29(5):744-8. PubMed ID: 21433222
[TBL] [Abstract][Full Text] [Related]
8. Moving beyond the comprehensive in vitro proarrhythmia assay: Use of human-induced pluripotent stem cell-derived cardiomyocytes to assess contractile effects associated with drug-induced structural cardiotoxicity.
Yang X; Papoian T
J Appl Toxicol; 2018 Sep; 38(9):1166-1176. PubMed ID: 29484688
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Batch Variations in Induced Pluripotent Stem Cell-Derived Human Cardiomyocytes from 2 Major Suppliers.
Huo J; Kamalakar A; Yang X; Word B; Stockbridge N; Lyn-Cook B; Pang L
Toxicol Sci; 2017 Mar; 156(1):25-38. PubMed ID: 28031415
[TBL] [Abstract][Full Text] [Related]
10. Cardiomyocytes derived from human pluripotent stem cells for drug screening.
Zeevi-Levin N; Itskovitz-Eldor J; Binah O
Pharmacol Ther; 2012 May; 134(2):180-8. PubMed ID: 22269465
[TBL] [Abstract][Full Text] [Related]
11. Cardiomyocytes derived from human embryonic stem cells - characteristics and utility for drug discovery.
Steel D; Hyllner J; Sartipy P
Curr Opin Drug Discov Devel; 2009 Jan; 12(1):133-40. PubMed ID: 19152222
[TBL] [Abstract][Full Text] [Related]
12. Safety pharmacology studies using EFP and impedance.
Obergrussberger A; Juhasz K; Thomas U; Stölzle-Feix S; Becker N; Dörr L; Beckler M; Bot C; George M; Fertig N
J Pharmacol Toxicol Methods; 2016; 81():223-32. PubMed ID: 27084108
[TBL] [Abstract][Full Text] [Related]
13. Functional and Transcriptional Characterization of Histone Deacetylase Inhibitor-Mediated Cardiac Adverse Effects in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
Kopljar I; Gallacher DJ; De Bondt A; Cougnaud L; Vlaminckx E; Van den Wyngaert I; Lu HR
Stem Cells Transl Med; 2016 May; 5(5):602-12. PubMed ID: 27034410
[TBL] [Abstract][Full Text] [Related]
14. Multi-parametric assessment of cardiomyocyte excitation-contraction coupling using impedance and field potential recording: A tool for cardiac safety assessment.
Zhang X; Guo L; Zeng H; White SL; Furniss M; Balasubramanian B; Lis E; Lagrutta A; Sannajust F; Zhao LL; Xi B; Wang X; Davis M; Abassi YA
J Pharmacol Toxicol Methods; 2016; 81():201-16. PubMed ID: 27282640
[TBL] [Abstract][Full Text] [Related]
15. The effects of cardioactive drugs on cardiomyocytes derived from human induced pluripotent stem cells.
Yokoo N; Baba S; Kaichi S; Niwa A; Mima T; Doi H; Yamanaka S; Nakahata T; Heike T
Biochem Biophys Res Commun; 2009 Sep; 387(3):482-8. PubMed ID: 19615974
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive in vitro cardiac safety assessment using human stem cell technology: Overview of CSAHi HEART initiative.
Takasuna K; Asakura K; Araki S; Ando H; Kazusa K; Kitaguchi T; Kunimatsu T; Suzuki S; Miyamoto N
J Pharmacol Toxicol Methods; 2017; 83():42-54. PubMed ID: 27646297
[TBL] [Abstract][Full Text] [Related]
17. Comparative analysis of media effects on human induced pluripotent stem cell-derived cardiomyocytes in proarrhythmia risk assessment.
Schocken D; Stohlman J; Vicente J; Chan D; Patel D; Matta MK; Patel V; Brock M; Millard D; Ross J; Strauss DG; Blinova K
J Pharmacol Toxicol Methods; 2018; 90():39-47. PubMed ID: 29155283
[TBL] [Abstract][Full Text] [Related]
18. High-throughput cardiac safety evaluation and multi-parameter arrhythmia profiling of cardiomyocytes using microelectrode arrays.
Gilchrist KH; Lewis GF; Gay EA; Sellgren KL; Grego S
Toxicol Appl Pharmacol; 2015 Oct; 288(2):249-57. PubMed ID: 26232523
[TBL] [Abstract][Full Text] [Related]
19. Comparison of electrophysiological data from human-induced pluripotent stem cell-derived cardiomyocytes to functional preclinical safety assays.
Harris K; Aylott M; Cui Y; Louttit JB; McMahon NC; Sridhar A
Toxicol Sci; 2013 Aug; 134(2):412-26. PubMed ID: 23690542
[TBL] [Abstract][Full Text] [Related]
20. Assessment of drug-induced arrhythmic risk using limit cycle and autocorrelation analysis of human iPSC-cardiomyocyte contractility.
Kirby RJ; Qi F; Phatak S; Smith LH; Malany S
Toxicol Appl Pharmacol; 2016 Aug; 305():250-258. PubMed ID: 27343406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
